IVVD
Invivyd Inc
NASDAQ · Biotechnology
$1.59
-0.12 (-7.02%)
Open$1.76
Previous Close$1.71
Day High$1.80
Day Low$1.58
52W High$3.07
52W Low$0.46
Volume—
Avg Volume3.57M
Market Cap440.63M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,250.9% upside
Current
$1.59
$1.59
Target
$21.48
$21.48
$15.01
$21.48 avg
$34.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 59.33M | 178.19M | 160.29M |
| Net Income | -397,200,152 | 4.92M | 3.11M |
| Profit Margin | -669.4% | 2.8% | 1.9% |
| EBITDA | -410,141,788 | 6.39M | 5.91M |
| Free Cash Flow | — | 2.75M | 2.88M |
| Rev Growth | — | +11.2% | +5.5% |
| Debt/Equity | — | 0.18 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |